No data available for drug.
Dosing & Uses
Drug Interaction
Adverse Reaction
Actions and Spectrum
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Administration
Patient Information Leaflet
DRUG INTERACTION
No drug interaction found for eletriptan and .
Contraindicated
bromocriptine
may have an increasingly adverse effect when combined with serotonin 5-HT1D receptor agonists
carprofen
may have an increased risk of hypertension when combined with eletriptan
Serious Use Alternative
ergonovine
may enhance the vasoconstricting effect of ergot Derivatives
cabergoline
may enhance the vasoconstricting effect of ergot Derivatives
tranylcypromine
may enhance the serotonergic effect of monoamine oxidase inhibitors
isocarboxazid
may enhance the serotonergic effect of monoamine oxidase inhibitors
phenelzine
may enhance the serotonergic effect of monoamine oxidase inhibitors
rasagiline
may enhance the serotonergic effect of monoamine oxidase inhibitors
safinamide
may enhance the serotonergic effect of monoamine oxidase inhibitors
curcumin
may increase the levels of serum concentration of eletriptan
glecaprevir
may increase the levels of serum concentration of eletriptan
caspofungin
may increase the levels of serum concentration of eletriptan
abiraterone
may increase the levels of serum concentration of eletriptan
mibefradil
may increase the levels of serum concentration of eletriptan
ergoloid mesylate
may have an increased vasoconstricting effect when combined with ergot derivatives
ergometrine
may have an increased vasoconstricting effect when combined with ergot derivatives
maralixibat
may enhance the concentration of serum when combined with eletriptan
lenacapavir
may enhance the concentration of serum when combined with eletriptan
ribociclib
CYP3A4 inhibitors increase the concentration of eletriptan in serum
diltiazem
may enhance the serum concentration of CYP3A4 inhibitors
ergonovine
may have an increased vasoconstricting effect when combined with ergot derivatives
dihydroergocristine
may have an increased vasoconstricting effect when combined with ergot derivatives
dihydroergotamine
may have an increased vasoconstricting effect when combined with ergot derivatives
ergoloid mesylate
may have an increased vasoconstricting effect when combined with ergot derivatives
ergometrine
may have an increased vasoconstricting effect when combined with ergot derivatives
tranylcypromine
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
isocarboxazid
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
safinamide
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
selegiline
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
phenelzine
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
sumatriptan
may have an increasingly adverse effect when combined with sumatriptan
rasagiline
serotonin 5-HT1D receptor agonists increase the serotonergic effect of MAO inhibitors
Monitor Closely
dexfenfluramine
may have an increased serotonergic effect when combined with serotonergic agents
lonafarnib
It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter
grapefruit
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
dexamethasone
It may enhance the metabolism when combined with dexamethasone
griseofulvin
It may diminish the effect when combined with griseofulvin by CYP3A4 metabolism
miconazole vaginal
It may enhance the effect when combined with miconazole vaginal by affecting CYP3A4 metabolism
droxidopa
may have an increased hypertensive effect when combined with droxidopa
rizatriptan
may increase the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists
Minor
No data available for drug.
Dosing & Uses
Adult
Pediatric
Geriatric
Drug Interaction
DRUG INTERACTION
eletriptan
&
No Drug Intearction Found. for eletriptan and .
Contraindicated
bromocriptine
may have an increasingly adverse effect when combined with serotonin 5-HT1D receptor agonists
carprofen
may have an increased risk of hypertension when combined with eletriptan
Serious Use Alternative
ergonovine
may enhance the vasoconstricting effect of ergot Derivatives
cabergoline
may enhance the vasoconstricting effect of ergot Derivatives
tranylcypromine
may enhance the serotonergic effect of monoamine oxidase inhibitors
isocarboxazid
may enhance the serotonergic effect of monoamine oxidase inhibitors
phenelzine
may enhance the serotonergic effect of monoamine oxidase inhibitors
rasagiline
may enhance the serotonergic effect of monoamine oxidase inhibitors
safinamide
may enhance the serotonergic effect of monoamine oxidase inhibitors
curcumin
may increase the levels of serum concentration of eletriptan
glecaprevir
may increase the levels of serum concentration of eletriptan
caspofungin
may increase the levels of serum concentration of eletriptan
abiraterone
may increase the levels of serum concentration of eletriptan
mibefradil
may increase the levels of serum concentration of eletriptan
ergoloid mesylate
may have an increased vasoconstricting effect when combined with ergot derivatives
ergometrine
may have an increased vasoconstricting effect when combined with ergot derivatives
maralixibat
may enhance the concentration of serum when combined with eletriptan
lenacapavir
may enhance the concentration of serum when combined with eletriptan
ribociclib
CYP3A4 inhibitors increase the concentration of eletriptan in serum
diltiazem
may enhance the serum concentration of CYP3A4 inhibitors
ergonovine
may have an increased vasoconstricting effect when combined with ergot derivatives
dihydroergocristine
may have an increased vasoconstricting effect when combined with ergot derivatives
dihydroergotamine
may have an increased vasoconstricting effect when combined with ergot derivatives
ergoloid mesylate
may have an increased vasoconstricting effect when combined with ergot derivatives
ergometrine
may have an increased vasoconstricting effect when combined with ergot derivatives
tranylcypromine
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
isocarboxazid
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
safinamide
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
selegiline
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
phenelzine
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
sumatriptan
may have an increasingly adverse effect when combined with sumatriptan
rasagiline
serotonin 5-HT1D receptor agonists increase the serotonergic effect of MAO inhibitors
Monitor Closely
dexfenfluramine
may have an increased serotonergic effect when combined with serotonergic agents
lonafarnib
It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter
grapefruit
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
dexamethasone
It may enhance the metabolism when combined with dexamethasone
griseofulvin
It may diminish the effect when combined with griseofulvin by CYP3A4 metabolism
miconazole vaginal
It may enhance the effect when combined with miconazole vaginal by affecting CYP3A4 metabolism
droxidopa
may have an increased hypertensive effect when combined with droxidopa
rizatriptan
may increase the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists
Minor
Actions and Spectrum
Adverse Reaction
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Administration
Patient Information Leaflet
medtigo
Action and Spectrum
Drug Interaction
Adverse Reaction
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Adminstartion
Patient Information Leaflet